Pharmacyclics Inc

Pharmacyclics — Technical Presentation (December 2012)

21 slides from Pharmacyclics's technical presentation, Dec 10, 2012

  1. Slide 1: Ibrutinib Promotes High Response Rate in CLL/SLL: Results of 116 Patients

    The Bruton’ s Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Promotes High Response Rate, Durable Remissions, and is Tolerable in Treatment Naive (TN) and Relapsed or Refractory (RR) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Patients Including Patients With High-R

  2. Slide 2: Bruton's Tyrosine Kinase (BTK)

    Bruton’s Tyrosine Kinase (BTK) A critical kinase for lymphoma cell survival and proliferation BTK is expressed and functional across non-T-cell hematopoietic lineages. BTK functions downstream in a variety of receptors, + Essential element of B-cell receptor signaling + Chemokine mediated migration

  3. Slide 3: Ibrutinib (PCI-32765)

    Ibrutinib (PCI-32765) A Selective Inhibitor of BTK NH, nm SS (ee, N’ N Forms a specific bond with cysteine- 481 in BTK Highly potent BTK inhibition at ICgo = 0.5 nM Orally administered with once daily dosing resulting in 24-hr target inhibition No cytotoxic effect on T-cells or natural killer (NK)-c

  4. Slide 4: Phase II in CLL/SLL

    PCYC-1102-CA Phase Il in CLL/SLL Enrolled May 2010July 2011 Treatment Naive (TN) 2 65 yrs 420 mg/d or 840 mg/d ibrutinib (n=31) Median follow-up 20.3 months PCYC-1102-CA 116 patients treated with ibrutinib monotherapy High-risk* Relapsed/Refractory (HR) 420 mg/d ibrutinib Endpoint: (n=24) Median fol

  5. Slide 5: Patient Characteristics

    PCYC-1102-CA Patient Characteristics ‘Age, years Median (Range) 2 70 years, (%) ECOG Status 0,1,2 B, Microglobulin > 3mg/L, % Rai Stage III/IV at Baseline Prognostic Markers, % IgV,, unmutated del(17p13.1) del(11q22.3) ‘TN 265 yrs R/R+HR (N=31) (N=85) 71 (65-84) 66 (37-82) 74% 35% 74%, 26%, 0% 41%,

  6. Slide 6: Patient Characteristics

    PCYC-1102-CA Patient Characteristics Median # Prior Rx (Range) <3 Prior Rx, % 23 Prior Rx, % ine Analog Refractory, % <12 mos from any PA to next therapy Prior therapy, % Nucleoside analog Alkylator Rituximab Alemtuzumab Bendamustine Ofatumumab Allo-SCT Investigational Therapies, % Lenalidomide BH3

  7. Slide 7: Patient Disposition

    PCYC-1102-CA Patient Disposition Median Time on Treatment, mos Range Subjects Still on Treatment, # (%) Primary Reasons for Treatment Discontinuation, # (%) Adverse Event (includes death) AE possibly or definitely related to ibrutinib (fatigue) Death due to AEt Disease Progression with transformatio

  8. Slide 8: Adverse Events

    Dizziness Dyspepsia Peripheral Edema ‘Arthralgia Constipation Hypertension Vomiting URI Gastroreflux disease Urinary tract infection TN RIR+HR (n=31) (n=85) Diarrhea uRt Fatigue cough Arthralgla Pyrexia Rash Peripheral Edema Muscle spasms Sinusitis Hypertension Constipation Dizziness Headache Nausea

  9. Slide 9: Safety

    PCYC-1102-CA Safety grade 3 Adverse events >: uonsajur g8=< Aue Infectious uopaayut e8=< Aue [ ejadonnan Qz eqwauy 8 equadoyooquiosy, ro ae [ 8 E a Hundonnen juadoyA20quiosy ejuownaug eowsueig equroneuodsH ysey g e1uowneug uonespAyed ejwaeieg Systemic 2 5% 50% 40% 30% 20% 10% 0% WGrade 3 MGrade 4 Mi

  10. Slide 10: Median Serum Immunoglobulin (Ig) Levels

    PCYC-1102-CA Median Serum Immunoglobulin (Ig) Levels Serum IgA Serum IgM Serum IgG STN (n=15) WR/R+ HR (n=15) GTN (n=12) MR/R+HR(n=10) TN (n=14) 1 R/R + HR (n=14) 200 60 50 150 40 z z 5100 B30 & & 2 | 50 10 ° ° Displayed with 96% Confidence interval

  11. Slide 11: Ibrutinib Improves Hemoglobin and Platelet Counts in Relapsed or Refractory Patients

    PCYC-1102-CA Ibrutinib Improves Hemoglobin and Platelet Counts in Relapsed or Refractory Patients With Cytopenia at Baseline 78% of 33 patients experienced sustained improvement of platelet counts 14, 82% of 41 patients experienced sustained improvement of hemoglobin 449 Z z ie 1208 B12 3 ° 2 # & _

  12. Slide 12: Response Criteria

    PCYC-1102-CA Response Criteria + CLL: The 2008 IWCLL criteria? were applied with the following clarifications in line with IWCLL/NCCN criteria (2012) : — PD: Treatment-related lymphocytosis, in the absence of other parameter, was not considered PD — PRwith lymphocytosis: a PR by other parameters + e

  13. Slide 13: Best Response

    PCYC-1102-CA Best Response 80% 5 60% ~ 40% - 20% 0% 68% } 10% 58% 13% 13% a« 0% Treatment Naive (n=31) 2 not evaluable 71% 2% Micr i PR 68% PRw WH i mphocytosis M@ sp 18% ™ Pb 4% om (13/85) 2/85. RIR + HR (n=85) 5 not evaluable 8

  14. Slide 14: Best Response by Risk Features

    PCYC-1102-CA Best Response by Risk Features Treatment Naive R/R+HR N ORR % N ORR % All Patients 31 68 85 71 270 years age 23 61 30 B B,Microglobulin >3mg/L 8 63 39 72 Rai Stage III/IV 1s 60 55 71 IgV, unmutated 17 82 69 we del(17p13.1) present a 100 28 68 del(11q22.3) present a 100 31 7 Bulky diseas

  15. Slide 15: IgVH and Lymphocytosis

    PCYC-1102-CA IgV,, and Lymphocytosis Relapsed/Refractory including High-Risk R/R 400 8 Median Percent Change from Baseline wi 959 Cls ~ 8 ° 8 8 8 = = IVH Mutated eV Unmutated Tes wn e Lymphocytosis, #(%) 10 (83) 53(77) Ns Lymphocytosis 5 (50) 45(85)_p=0.025 Normalized, # (%)* Median Time to 148 64 p

  16. Slide 16: Progression-free Survival

    rogression-free Survival Relapsed/Refractory and Treatment N. 65yrs 10 08 2 Bo6 s 5 — RIR + High-Risk R/R (n=85) © 4 Est. PFS at 26 mo is 75% : —— Treatment Naive (n=31) Est. PFS at 26 mo is 96% 02 + Consored 0.0 Logrank p=0.0256 Data cut-off of 190CT2012 a) 5 10 15 20 25 Months on Study .

  17. Slide 17: Progression-free Survival

    Progression-free Survival Relapsed/Refractory including High-Risk R/R del(17p13.1)/del(11q22.3) Status IgV, Status 10 os os 08 z B06 — datt7p (n=28) pe Est PPS at 20 mo is 57% — Mutts n=12) 7 — aettig n=23) os Est PFS at 26 mois 65% Fa Est PS at 20 mo is 73% — Unmutated re 63) PS — No delt7p or dett

  18. Slide 18: Overall Survival: Relapsed/Refractory and Treatment Naive >= 65yrs

    Relapsed/Refractory and Treatment Naive >= 65yrs ee eee g 8g 2 ia Q fe} 1.0 0.4 02 0.0 + Censored 0 Logrank p=0.0987 — RIR + High-Risk R/R (n=85) Est. OS at 26 mo is 83% — Treatment Naive (n=31) Est. OS at 26 mo is 96% Data cut-off of 190CT2012 10 15 20 25 Months on Study 8

  19. Slide 19: OS Probability

    0S Probability verall Surviva' Relapsed/Refractory including High-Risk R/R del(17p13.1)/del(11q22.3) Status IgV, Status ey 105 - T 4 os TEE esatasmois7on O° st OS at 26 m0 — einigne23) 4 Est OS 3126 mois 65% Est, OS at 26 mois 85% a — Unmnutated (n=69) Ns aets7p or det 19 (ne 29) Est OS a 28 mos 82%

  20. Slide 20: Summary

    PCYC-1102-CA Summary + Ibrutinib as a single agent in induces a high response in all populations studied + The PFS and OS was prolonged in both previously untreated and relapsed and refractory patients as compared to historical controls + Outcome of high-risk patients such as del 17p appears to be s

  21. Slide 21: Acknowledgement

    PCYC-1102-CA Acknowledgement All of the patients and their supportive families who participated in the study Investigators and clinical research staff from all the Anh Tran Sheila Lagura Stephen Chan Tosh Kameda Raymond Lee Julie Graves Clara Plascencia Joyce Martin clinical centers Pharmacyclics, I

Pharmacyclics — Technical Presentation (December 2012) on 6ix